CN108956790A - Application of one group of amino acid tags object in acute kidney injury diagnostic kit - Google Patents

Application of one group of amino acid tags object in acute kidney injury diagnostic kit Download PDF

Info

Publication number
CN108956790A
CN108956790A CN201710353982.6A CN201710353982A CN108956790A CN 108956790 A CN108956790 A CN 108956790A CN 201710353982 A CN201710353982 A CN 201710353982A CN 108956790 A CN108956790 A CN 108956790A
Authority
CN
China
Prior art keywords
acid
amino acid
kit
reagent
kidney injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201710353982.6A
Other languages
Chinese (zh)
Inventor
张凤
陶霞
陈万生
朱桑
夏天
夏天一
翟健秀
龚晓斌
高守红
王清华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Affiliated Hospital Army Medical University
Original Assignee
Second Affiliated Hospital Army Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Affiliated Hospital Army Medical University filed Critical Second Affiliated Hospital Army Medical University
Priority to CN201710353982.6A priority Critical patent/CN108956790A/en
Publication of CN108956790A publication Critical patent/CN108956790A/en
Pending legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to kit for diagnosing diseases field, specifically one group of amino acid tags object is preparing the application in acute kidney injury diagnostic reagent or kit, and the amino acid tags object is selected from kynurenin, one or more of hippuric acid and Pidolic Acid.3 amino acid tags objects proposed by the present invention can be in the generation of acute kidney injury early stage Accurate Diagnosis disease, and AUC value is all larger than 0.7 when being individually used for diagnosis acute kidney injury, and it is preferable that effect is distinguished in diagnosis.Wherein kynurenin and hippuric acid diagnosis capability are better than clinical common renal function marker creatinine and early diagnosis marker NGAL, and above-mentioned 3 amino acid is to the Diagnostic Time of AKI earlier than clinical renal function marker urea nitrogen.Targeting amino acid metabolism group detection method provided by the invention can be achieved at the same time the quantitative analyses of multiple amino acid, high sensitivity, as a result accurately and reliably.

Description

Application of one group of amino acid tags object in acute kidney injury diagnostic kit
Technical field
The present invention relates to kit for diagnosing diseases fields, specifically, being three kinds of amino acid tags objects in acute kidney injury Application in diagnostic kit.
Background technique
Acute kidney injury (AKI) is a kind of impaired morbid state of kidney structure and function, to happen suddenly and lasting kidney function It can decline and be characterized, be as caused by different pathogeny, be related to the clinical syndrome of each systemic symptom of whole body.Slight injury of kidney can Voluntarily to restore over time, even if AKI patient is relieved, long-term cardiovascular risk still be will increase.Severe It must receive dialysis treatment when AKI patient's lesion progress to kidney failure.There are about 2,900,000 inpatients to suffer from AKI for China in 2013, The death rate about 24%.AKI increases Hospitalization Expenses of Inpatients and the death rate, while causing the waste of medical resource.
Improve in the clinical practice guideline (KDIGO guide) that global kidney trouble prognosis tissue 2012 is formulated with serum creatinine and urine Amount is standard, and AKI is defined as to the generation of following either case, is increased in SCr 48 hours up to >=0.3mg/dL (26.5 μm of ol/ L);Or Scr increased in 7 days up to basic value >=1.5 times;Or urine volume < 0.5mL/kg/h continues 6 hours.Glomerular filtration rate Rapid decrease can be increased by SCr and hypourocrinia is reacted, diagnosis effect be verified extensively.However, serum creatinine Level variation is more slow, and urine volume is affected to the assessment of glomerular filtration rate by blood volume, based on serum creatinine and urine volume Variation is difficult to accomplish early detection and accurate evaluation injury of kidney.Research shows that the damage of kidney is can to reverse after acute kidney injury , the AKI diagnosis of early stage can accurately find that AKI patient makes it obtain timely therapeutic intervention, reduces the degree of injury of kidney. Excavating new AKI early warning marker helps to solve the underdiagnosis of current AKI, makes patient can be by disease early stage It was found that.
With the development of genomics, protein science and metabolism group, the excavation research of AKI early diagnosis marker is continuous Deeply.The specific protein expressed and secreted when presently found AKI early warning marker is mostly renal damage, wherein neutral Granulocyte gelatinase correlation apolipoprotein (NGAL) report is more, shows preferably to examine in experimental animal and clinical patient The disconnected effect and time is earlier than conventional sign object creatinine, but its detection method is increasingly complex compared with the small molecules marker such as creatinine, adopts more It is detected with enzyme-linked immunization.This method sensitivity and specificity are higher, but the cumbersome detection time of operating process is long, and matrix In metabolin may occur cross reaction interference measurement result with antibody.
Kidney participates in the metabolism of a variety of amino acid and discharge process in vivo, tune of the vivo acid level by renal function Section, renal function is damaged occurs disorder of amino acid metabolism often.Recent study discovery, a variety of amino acid levels and kidney The renal function of Disease is significant related to prognosis, as Ng,Ng-Dimethylarginine, symmetrical dimethylarginine, S- adenosine are same Type cysteine etc..It can be seen that complete renal function plays a significant role in maintaining amino acid cycle level, amino acid is made A new target group of AKI early diagnosis are likely to become for the small molecule metabolites of metabolic chain terminal.Using targeting amino Acid metabolic omics technology, which excavates effective amino acid tags object, has important meaning for clinical Rapid&Early diagnosis acute kidney injury Justice.
Summary of the invention
For overcome the deficiencies in the prior art, the first object of the present invention is that providing 3 can be used for diagnosing acute kidney The amino acid tags object of damage;The second object of the present invention, which is to provide, a kind of is capable of amino acid tags object described in simultaneous quantitative Analysis method.Above-mentioned purpose technical scheme is that: one group for diagnosing the plasma ammonia of acute kidney injury Base acid marker, including kynurenin, hippuric acid and Pidolic Acid.A kind of method of amino acid tags object described in quantitative analysis, Quantitative analysis carried out to the amino acid tags object by high performance liquid chromatography tandem mass spectrum technology, this method have it is high-throughput and Highly sensitive feature can satisfy the quantitative detection of metabolin in biological sample.
The first aspect of the present invention provides one group for diagnosing the Amino Acid marker of acute kidney injury, including dog Urinary ammonia acid, hippuric acid and Pidolic Acid.
The second aspect of the present invention provides one group of amino acid tags object and is preparing acute kidney injury diagnostic reagent or kit In application, the amino acid tags object be selected from kynurenin, one or more of hippuric acid and Pidolic Acid.
Preferably, the diagnostic reagent or kit are serodiagnosis reagent or diagnostic kit.
Preferably, kynurenin in the diagnostic reagent or kit detection serum, in hippuric acid and Pidolic Acid One or more kinds of contents.
Preferably, the diagnostic reagent or kit are to be detected in serum using high performance liquid chromatography tandem mass spectrum technology Kynurenin, the combination of the reagent of one or more of hippuric acid and Pidolic Acid content.
The third aspect of the present invention, provides a kind of acute kidney injury diagnostic reagent or kit, the diagnostic reagent or It include kynurenin in detection serum, the reagent of one or more of hippuric acid and Pidolic Acid content in kit.
The fourth aspect of the present invention provides kynurenin in detection serum, one of hippuric acid and Pidolic Acid or two Kind or more the reagent of content preparing the application in acute kidney injury diagnostic kit.
Preferably, the reagent is to detect kynurenin in serum, horse using high performance liquid chromatography tandem mass spectrum technology The reagent of one or more of uric acid and Pidolic Acid content.
The invention has the advantages that:
Amino acid tags object provided by the invention can be examined in acute kidney injury early stage Accurate Diagnosis disease, each marker Disconnected value is evaluated with ROC curve analysis, and theoretically area AUC value is between 0.5 to 1 under ROC curve, and value is closer to 1 Diagnostic value is bigger, and AUC value indicates that result has clinical meaning between 0.7 to 0.9.3 amino acidity scales proposed by the present invention Will object it is big can be individually used for AUC value when diagnosis acute kidney injury in the generation of acute kidney injury early stage Accurate Diagnosis disease In 0.7, it is preferable that effect is distinguished in diagnosis.Wherein kynurenin and hippuric acid diagnosis capability are better than clinical common renal function marker flesh Acid anhydride and early diagnosis marker NGAL, above-mentioned 3 amino acid urinate the Diagnostic Time of AKI earlier than clinical renal function marker Plain nitrogen.Targeting amino acid metabolism group detection method provided by the invention can be achieved at the same time the quantitative analysis of multiple amino acid, High sensitivity, as a result accurately and reliably.
Detailed description of the invention
Fig. 1 rat blood serum creatinine, urea nitrogen and NGAL concentration time curve;
Fig. 2 rat blood serum different amino acids Concentration-time change curve.
Specific embodiment
It elaborates below with reference to embodiment to specific embodiment provided by the invention.The instrument or reagent used is not What is elaborated is conventional instrument or reagent;The experimental working technique not specifically described is those of ordinary skill in the art Well known conventional practices.
Embodiment 1: the screening of renal ischemia/reperfusion injury rat and sham-operation rat blood serum difference acidic amino acid
One, object and method
1. animal model preparation and grouping
Male Sprague-Dawley (SD) rat, weight 180-200g are mentioned by The 2nd Army Medical College Experimental Animal Center For.Rat feeding is tested after a week to adapt to environment, and about 25 DEG C of animal house room temperature, relative humidity about 60%, during raising Rat diet drinking-water freely, keeps each 12 hours light and shades round the clock, and testing preceding 8 hours Rat Fasts can't help water.Animal is divided at random For control group and AKI group, every group 30, respectively 0 after Reperfu- sion, 2,4,6,10, take a blood sample for 24 hours through retroorbital venous clump, room temperature Serum sample is separated after blood coagulation.AKI group rat is routinely opened with 10% chloraldurate 0.35mL/100g weight intraperitoneal injection of anesthesia Abdomen successively exposes bilateral renal, and artery clamp folder closes bilateral renal arteries, unclamps artery clamp kidney after ischemic 50min and restore perfusion, Layer-by-layer suture.Control rats are not pressed from both sides by above process exposure kidney and close the arteria renalis, sutured abdominal cavity after 50min.
2. main agents
Enzymic creatinine assay method creatinine assay kit (Nanjing is built up, article No. C011-2), urease method determination of urea nitrogen examination Agent box (Nanjing is built up, article No. C013-2), rat NGAL detect Elisa kit (Wuhan doctor's moral, article No. EK0855), phosphoric acid Salt buffer (PBS;Shanghai English fine horse biology), bovine serum albumin(BSA) (BSA;Win photo-biological company in Shanghai), hyptafluorobutyric acid (HFBA; Adamas, Switzerland), formic acid (FA;U.S. world company);Hippuric acid (Hip), kynurenin (Kyn), symmetrical dimethylarginine (SDMA), Pidolic Acid (Oxo), glutamine (Gln), 6 kinds of amino acid standards such as amidomalonic acid (AMA) are purchased from Dalian beauty Logical sequence biotechnology company;Remaining 17 kinds of amino acid standard is purchased from Chinese pharmaceutical biological product and identifies institute (batch number 140624- 200805), including lysine (Lys), tryptophan (Trp), leucine (Leu), isoleucine (Iso), phenylalanine (Phe), Methionine (Met), threonine (Thr), valine (Val), glycine (Gly), alanine (Ala), arginine (Arg), silk Propylhomoserin (Ser), L-aminobutanedioic acid (Asp), tyrosine (Tyr), cysteine (Cys), histidine (His), glutamic acid (Glu);Deuterium For alanine (L-Ala-d4;North York, Canada), deuterated methionine (L-Met-d3;North York, adds and takes Greatly), deuterated phenylalanine (L-Phe-d5;North York, Canada), analyze pure methanol and acetonitrile (Merk, Germany).
3. serum amino acid and the detection of other renal function index
The screening of 3.1 serum different amino acids
3.1.1 sample preparation
Using precipitation of protein, precipitating reagent is containing 0.2% formic acid and each interior target acetonitrile solution of 0.4 μ g/mL.Take 50 μ L blood The precipitating reagent 150 μ L of pre-cooling is added in 1.5mL centrifuge tube in sample, and vortex 30s is placed on ultrasound 5min in ice water and sufficiently precipitates egg It is white.Then 13000rpm high speed centrifugation is centrifuged 10min.Supernatant liquor is taken to carry out LC-MS/MS analysis, all operations are on ice It carries out.
3.1.2 LC-MS/MS testing conditions
Chromatography uses ultra performance liquid chromatography (UHPLC, Agilent 1290, USA).Chromatographic column is Agilent ZORBAX SB-C18 column (5 μm, 3.0mm × 150mm), 4 DEG C of autosampler temperature, 50 DEG C of column temperature, 2 μ L of sampling volume, flowing It is mutually A (methanol solution), B (aqueous solution containing 0.2% formic acid and 0.02% hyptafluorobutyric acid), flow velocity 0.4mL/min;Gradient is washed De- condition: 0~1min is 98~85%B phase, and 1~4min keeps 85%B phase to elute, and 4~5min is 85-80%B phase, 5- 9.5min is 80-20%B phase.Data acquisition time is 9.5min, rear runing time 3.5min, when completing primary analysis always operation Between 13min.
Mass spectral analysis uses triple quadrupole rods tandem mass spectrometries (Agilent 6460QQQ, USA).Electric spray ion source (ESI), scanning mode is multiple-reaction monitoring (MRM) mode, positive ion mode monitoring, spray voltage 5000V;Atomizing pressure is 50psi;Dry 325 DEG C of flow velocitys of temperature degree are 10L/min;350 DEG C of flow velocity 12L/min of sheath temperature degree.23 components to be measured and 3 The detection parameters of internal standard compound are shown in Table 1, including F value (Fragmentor), CE value (Collisine Energy), parent ion (Precusor Ion), daughter ion (Product Ion).
Each amino acid standard curve range are as follows: Cys and Hip (0.008-12 μ g/mL);Kyn, Asp, SDMA, Arg (0.08- 8μg/mL);AMA, His, Met, Ser (0.05-12 μ g/mL);Glu, Thr, Gln (0.8-40 μ g/mL);Iso, Leu, Tyr, Phe, Lys, Val (2-48 μ g/mL);Gly, Oxo (2-60 μ g/mL);Ala(4-120μg/mL)
The MS detection parameters of table 1 23 kinds of amino acid and 3 internal standard compounds
3.2 creatinine urea nitrogens and NGAL detection
Serum creatinine level is measured using enzymic creatinine assay method, urease method measures serum urea nitrogen level, enzyme linked immunological It is horizontal that method measures serum N GAL.The detection of each index is all made of commercial kit, and detection process requires to carry out to specifications Operation.
4. data process&analysis
Statistical analysis uses SPSS19.0 software, since each Testing index disobeys normal distribution, with median ± tetra- point Position is away from expression.Mean value compares using non-parametric rank sum test between two groups, and p < 0.05 thinks that difference has statistical difference.Difference ammonia The screening of base acid is carried out using 13.0 software of SIMCA, by establishing OPLS-DA (orthogonal partial least squares discriminant analysis) model, is sought It looks between acute kidney injury rat and sham-operation rat and contributes larger (VIP > 1.0;P < 0.05) different amino acids.
Two, result
Two groups of rat baseline renal function index are consistent, and the postoperative serum creatinine of AKI group rat and urea nitrogen levels increase immediately, 2 hours serum creatinines of Reperfu- sion and urea nitrogen are significantly higher than control group, hereafter continue to be increased to reach maximum value in 24 hours.By above Renal ischemia/reperfusion injury known to renal function index variation causes rat acute injury of kidney, Animal Model success.AKI group rat The horizontal progressive of serum N GAL increases (Fig. 1) consistent with document report.
Screening obtains 3 different amino acids, respectively kynurenin, hippuric acid and Pidolic Acid altogether;Above-mentioned amino acid exists The selected different amino acids of each detection time point after AKI occurs.Above-mentioned 3 serum different amino acids press horizontal mobile after AKI occurs Fig. 2 is shown in state variation.Kynurenine levels increase immediately after kidney injury, reach peak within Reperfu- sion 1 hour, hereafter gradually return It falls but is consistently higher than control group.Hippuric acid level is significantly higher than control group in 1 hour after kidney injury, and hereafter 24 hours Interior lasting raising.Serum Pidolic Acid level gradually rises after AKI occurs, until Reperfu- sion 10 hours begin to decline;Control group is big The horizontal Reperfu- sion of mouse Pidolic Acid is presented in 4 hours and is increased by a small margin, then begins to decline, until increasing again after 12 hours.By This can be used in acute kidney injury as it can be seen that above-mentioned 3 different amino acids levels show significantly to change after acute kidney injury Early diagnosis.
Embodiment 2: building ROC curve compares the ability of 3 serum different amino acids diagnosis acute kidney injury
Using the assessment of the above-mentioned different amino acids diagnosis capability of receiver operating curves (ROC) progress, and and creatinine, urea Nitrogen and NGAL are compared.Above-mentioned 3 different amino acids, traditional renal function marker creatinine and urea nitrogen, and early diagnosis Marker NGAL, which is individually used for diagnosis AKI, the results are shown in Table 1.The results show that kynurenin, 3 ammonia of hippuric acid and Pidolic Acid The ability that base acid marker is individually used for diagnosis acute kidney injury is stronger, and area (AUC) is all larger than 0.7 under ROC curve, has and faces Bed diagnostic significance.1 hour 3 amino acid tags object of beginning and creatinine and NGAL level are shown preferably after kidney injury AKI diagnosis capability, diagnosis capability is by being followed successively by kynurenin, hippuric acid, NGAL, creatinine and Pidolic Acid to weak by force;AUC value point It Wei 1.00,0.97,0.91,0.82 and 0.79.Urea nitrogen levels more lag the diagnosis of AKI, open within 2 hours after kidney injury Begin that there is diagnostic effect.It can be seen that kynurenin and hippuric acid are to the diagnosis capability of AKI better than common kidney in clinic at present Functional parameter creatinine and early sign object NGAL, three different amino acids are on Diagnostic Time earlier than the common renal function of clinic Index urea nitrogen.Therefore, above-mentioned 3 amino acid can be used as acute kidney injury diagnosis marker.
The diagnosis situation of 1 rat blood serum amino acid tags object of table, creatinine, urea nitrogen and NGAL to AKI
The preferred embodiment of the present invention has been described in detail above, but the invention be not limited to it is described Embodiment, those skilled in the art can also make various equivalent on the premise of not violating the inventive spirit of the present invention Variation or replacement, these equivalent variation or replacement are all included in the scope defined by the claims of the present application.

Claims (7)

1. one group of amino acid tags object is preparing the application in acute kidney injury diagnostic reagent or kit, the amino acidity scale Will object is selected from kynurenin, one or more of hippuric acid and Pidolic Acid.
2. one group of amino acid tags object according to claim 1 is in preparing acute kidney injury diagnostic reagent or kit Using, which is characterized in that the diagnostic reagent or kit is serodiagnosis reagent or diagnostic kit.
3. one group of amino acid tags object according to claim 1 is in preparing acute kidney injury diagnostic reagent or kit Using kynurenin in, which is characterized in that the diagnostic reagent or kit detection serum, in hippuric acid and Pidolic Acid One or more kinds of contents.
4. one group of amino acid tags object according to claim 1 is in preparing acute kidney injury diagnostic reagent or kit Using, which is characterized in that the diagnostic reagent or kit is to detect serum using high performance liquid chromatography tandem mass spectrum technology Middle kynurenin, the combination of the reagent of one or more of hippuric acid and Pidolic Acid content.
5. a kind of acute kidney injury diagnostic reagent or kit, which is characterized in that include in the diagnostic reagent or kit Detect kynurenin in serum, the reagent of one or more of hippuric acid and Pidolic Acid content.
6. detecting kynurenin in serum, the reagent of one or more of hippuric acid and Pidolic Acid content is anxious in preparation Application in property injury of kidney diagnostic kit.
7. kynurenin in detection serum according to claim 6, one or both of hippuric acid and Pidolic Acid with The reagent of upper content is preparing the application in acute kidney injury diagnostic kit, which is characterized in that the reagent is using high Effect liquid phase chromatogram tandem mass spectrometry detects kynurenin in serum, and one or more of hippuric acid and Pidolic Acid contain The reagent of amount.
CN201710353982.6A 2017-05-18 2017-05-18 Application of one group of amino acid tags object in acute kidney injury diagnostic kit Pending CN108956790A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710353982.6A CN108956790A (en) 2017-05-18 2017-05-18 Application of one group of amino acid tags object in acute kidney injury diagnostic kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710353982.6A CN108956790A (en) 2017-05-18 2017-05-18 Application of one group of amino acid tags object in acute kidney injury diagnostic kit

Publications (1)

Publication Number Publication Date
CN108956790A true CN108956790A (en) 2018-12-07

Family

ID=64461930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710353982.6A Pending CN108956790A (en) 2017-05-18 2017-05-18 Application of one group of amino acid tags object in acute kidney injury diagnostic kit

Country Status (1)

Country Link
CN (1) CN108956790A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110907569A (en) * 2019-12-25 2020-03-24 山东英盛生物技术有限公司 Method for simultaneously detecting 4 protein-bound uremia toxins in blood sample
CN112180017A (en) * 2019-11-20 2021-01-05 南京品生医学检验实验室有限公司 Method and kit for detecting ADMA (adenosine triphosphate) and SDMA (space division multiple Access) in plasma by ultra-high performance liquid chromatography tandem mass spectrometry
CN114487214A (en) * 2022-01-24 2022-05-13 广州市番禺区中心医院 Biomarker for distinguishing benign prostatic hyperplasia and prostatitis and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1153784A (en) * 1995-09-14 1997-07-09 默克专利股份有限公司 Biotin derivatives
CN101776662A (en) * 2010-01-15 2010-07-14 中南大学湘雅二医院 Method for simultaneously determining tryptophan, kynurenine and kynurenicacid by using high performance liquid chromatography-fluorescence method
CN103033580A (en) * 2013-01-06 2013-04-10 浙江中烟工业有限责任公司 Detecting method for lung cancer characteristic metabolite fingerprint spectrum in urine
CN105209909A (en) * 2013-05-14 2015-12-30 梅塔博隆股份有限公司 Biomarkers related to kidney function and methods using the same
US20160116461A1 (en) * 2006-10-13 2016-04-28 Metabolon, Inc. Biomarkers Related To Metabolic Age and Methods Using The Same

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1153784A (en) * 1995-09-14 1997-07-09 默克专利股份有限公司 Biotin derivatives
US20160116461A1 (en) * 2006-10-13 2016-04-28 Metabolon, Inc. Biomarkers Related To Metabolic Age and Methods Using The Same
CN101776662A (en) * 2010-01-15 2010-07-14 中南大学湘雅二医院 Method for simultaneously determining tryptophan, kynurenine and kynurenicacid by using high performance liquid chromatography-fluorescence method
CN103033580A (en) * 2013-01-06 2013-04-10 浙江中烟工业有限责任公司 Detecting method for lung cancer characteristic metabolite fingerprint spectrum in urine
CN105209909A (en) * 2013-05-14 2015-12-30 梅塔博隆股份有限公司 Biomarkers related to kidney function and methods using the same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHRISTOPH REICHETZEDER ET AL: "Pre-Interventional Kynurenine Predicts Medium-Term Outcome after Contrast Media Exposure Due to Coronary Angiography", 《KIDNEY BLOOD PRESSURE RESEARCH》 *
JINCHUN SUN ET AL: "Serum metabolomic profiles from patients with acute kidney injury: A pilot study", 《JOURNAL OF CHROMATOGRAPHY B》 *
LIQIANG GU ET AL: "simultaneous Determination of Five Specific and Sensitive Nephrotoxicity Biomarkers in Serum and Urine Samples of Four Drug-Induced Kidney Injury Models", 《JOURNAL OF CHROMATOGRAPHIC SCIENCE》 *
YU JIANG ET AL: "Evaluation of the indicative roles of seven potential biomarkers on hepato-nephrotoxicity induced by Genkwa Flos", 《JOURNAL OF ETHNOPHARMACOLOGY》 *
钟凌云 等: "基于代谢组学的不同姜汁制黄连药性的比较研究", 《中国中药杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112180017A (en) * 2019-11-20 2021-01-05 南京品生医学检验实验室有限公司 Method and kit for detecting ADMA (adenosine triphosphate) and SDMA (space division multiple Access) in plasma by ultra-high performance liquid chromatography tandem mass spectrometry
CN110907569A (en) * 2019-12-25 2020-03-24 山东英盛生物技术有限公司 Method for simultaneously detecting 4 protein-bound uremia toxins in blood sample
CN114487214A (en) * 2022-01-24 2022-05-13 广州市番禺区中心医院 Biomarker for distinguishing benign prostatic hyperplasia and prostatitis and application thereof
CN114487214B (en) * 2022-01-24 2024-05-14 广州市番禺区中心医院 Biomarker for distinguishing benign prostatic hyperplasia and prostatitis and application thereof

Similar Documents

Publication Publication Date Title
Tsikas et al. Homoarginine, arginine, and relatives: analysis, metabolism, transport, physiology, and pathology
Zhang et al. Distinguish ing Intracerebral Hemorrhage from Acute Cerebral Infarction through Metabolomics
Li et al. A visible and near-infrared dual-fluorescent probe for discrimination between Cys/Hcy and GSH and its application in bioimaging
Castagna et al. Hepcidin assay in serum by SELDI-TOF-MS and other approaches
CN108956790A (en) Application of one group of amino acid tags object in acute kidney injury diagnostic kit
Mao et al. Simultaneous determination of l-citrulline and l-arginine in plasma by high performance liquid chromatography
DK2333552T3 (en) New biomarkers for non-alcoholic fatty liver, and methods for the detection of non-alcoholic fatty liver using a biomarker
Smith et al. The measurement of tissue protein turnover
CN103389383A (en) Detection kit for measuring content of myohemoglobin in serum
CN104634907B (en) Application of amino acid molecular combination as gastric cancer marker
Gucinski et al. Modern analytics for naturally derived complex drug substances: NMR and MS tests for protamine sulfate from chum salmon
Zhou et al. Irisin and volume overload are associated with protein energy wasting in peritoneal dialysis patients
CN105988001A (en) Reagent kit and method for measuring concentration of asymmetric dimethylarginine
Mhike et al. Characterization of methylene diphenyl diisocyanate-haptenated human serum albumin and hemoglobin
CN108896771B (en) Use of GUCA2A protein in osteoarthritis
WO2016127278A1 (en) Application of urine complement component 3 (c3) protein
CN107290552B (en) The biomarker of high coagulation and its application
CN105158474A (en) Reagent kit for detecting serum HER2 and application
EP2859354B1 (en) Nitrated cardiac troponin i as a biomarker of cardiac ischemia
Cisneros et al. Identification of Potential Visceral Pain Biomarkers in Colon Exudates from Mice with Experimental Colitis: An Exploratory In Vitro Study
WO2007107334A1 (en) Ex vivo cancer diagnostic method
Kakinuma et al. Quantification of hydroxyproline in small amounts of skin tissue using isocratic high performance liquid chromatography with NBD-F as fluorogenic reagent
CN110133285B (en) Detection reagent, kit and method for detecting anti-liver cancer natural antibody
US8697368B2 (en) Diagnostic marker for lung cancer comprising HPαR as active ingredient
WO2022091793A1 (en) Development of pancreatic cancer biomarker using feces-derived protein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20181207